Can i use cbd oil for ptsd in missouri

Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review

Medicinal cannabis has received increased research attention over recent years due to loosening global regulatory changes. Medicinal cannabis has been reported to have potential efficacy in reducing pain, muscle spasticity, chemotherapy-induced nausea and vomiting, and intractable childhood epilepsy. Yet its potential application in the field of psychiatry is lesser known.

Methods

The first clinically-focused systematic review on the emerging medical application of cannabis across all major psychiatric disorders was conducted. Current evidence regarding whole plant formulations and plant-derived cannabinoid isolates in mood, anxiety, sleep, psychotic disorders and attention deficit/hyperactivity disorder (ADHD) is discussed; while also detailing clinical prescription considerations (including pharmacogenomics), occupational and public health elements, and future research recommendations. The systematic review of the literature was conducted during 2019, assessing the data from all case studies and clinical trials involving medicinal cannabis or plant-derived isolates for all major psychiatric disorders (neurological conditions and pain were omitted).

Results

The present evidence in the emerging field of cannabinoid therapeutics in psychiatry is nascent, and thereby it is currently premature to recommend cannabinoid-based interventions. Isolated positive studies have, however, revealed tentative support for cannabinoids (namely cannabidiol; CBD) for reducing social anxiety; with mixed (mainly positive) evidence for adjunctive use in schizophrenia. Case studies suggest that medicinal cannabis may be beneficial for improving sleep and post-traumatic stress disorder, however evidence is currently weak. Preliminary research findings indicate no benefit for depression from high delta-9 tetrahydrocannabinol (THC) therapeutics, or for CBD in mania. One isolated study indicates some potential efficacy for an oral cannabinoid/terpene combination in ADHD. Clinical prescriptive consideration involves caution in the use of high-THC formulations (avoidance in youth, and in people with anxiety or psychotic disorders), gradual titration, regular assessment, and caution in cardiovascular and respiratory disorders, pregnancy and breast-feeding.

Conclusions

There is currently encouraging, albeit embryonic, evidence for medicinal cannabis in the treatment of a range of psychiatric disorders. Supportive findings are emerging for some key isolates, however, clinicians need to be mindful of a range of prescriptive and occupational safety considerations, especially if initiating higher dose THC formulas.

Introduction

The Cannabaceae family is a comparatively small family of flowering plants encompassing 11 genera and approximately 170 different species, a small number of which elicit a range of varying psychoactive effects [1]. Several medical applications have been studied over the past decades, with the National Academies of Sciences, Engineering and Medicine (NASEM) recently holding the position that cannabis and cannabinoids demonstrate conclusive or substantial evidence for chronic pain in adults, chemotherapy-induced nausea and vomiting and spasticity in multiple sclerosis, with limited evidence for use in increasing appetite in HIV/AIDS patients and improving symptoms of post-traumatic stress disorder (PTSD) [2].

While there is increasing psychiatric interest (and debate) regarding the potential mental health applications (in concert with concerns over the potential for triggering latent psychosis), historical evidence for the use of cannabis in mental health conditions is remarkably ancient. For instance, the Shen-nung Pen-tsao Ching (Divine Husbandman’s Materia Medica) described its benefit as an anti-senility agent [3, 4], while in the Assyrian culture, cannabis was indicated as a drug for grief and sorrow [5, 6]. Sections of the Indian Atharva Veda (1500 BCE) suggest bhanga (Cannabis) exerted anxiolytic effects [5, 7], while in 1563, Da Orta [8] described cannabis as allaying anxiety and engendering laughter. With respect to modern use, contemporary consumers of cannabis report (as assessed via meta-analysis of patient usage data) that pain (64%), anxiety (50%), and depression/mood (34%) are the most common reasons [9].

Increasing scientific research, conducted over recent years, has seen the regulatory pendulum swinging away from the United Nations Single Convention on Narcotic Drugs in 1961 (which recommends enforcement of cannabis use as illegal) [10], towards consideration of its potential use in medical conditions. Recent scientific evidence ascribes anxiolytic, neuroprotective, antioxidant, anti-inflammatory, antidepressant, anti-psychotic and hypnotic pharmacological actions due to several phytochemicals commonly found in the cannabis genus [11, 12].

While Δ 9 -tetrahydrocannabinol (THC) is considered the main psychoactive constituent, other cannabinoids have also revealed less potent psychotropic effects. These include cannabidiol (CBD) [13], Δ 8 -tetrahydrocannabinol [14], and other less-studied cannabinoids including cannabinol (CBN) and Δ 8 tetrahydrocannabivarin (THCV) [15]. Further, many other constituents such as the terpenes (i.e. volatile organic compounds found mainly as essential oils in many plants), also provoke a range of biological effects, and produce the characteristic aroma of the plant [16]. The hundreds of cannabis chemovars or varieties (commonly referred to as strains) developed over millennia have unique and complex constituent profiles, of which each may provide targeted therapeutic usage due to the unique synergistic combination of plant chemicals. Some pharmaceutical preparations have attempted to isolate the key constituents (there are over 140 phytocannabinoids [17]) to provide standardised formulas that may harness this ‘entourage effect’ [16, 18], while being able to provide batch-to-batch assurance of the medicine.

While other reviews have covered cannabis’ use in a range of conditions (cf. Whiting et al. 2015 [10] for a general review of evidence for medicinal cannabis), none to date have provided both a systematic and ‘clinically-focused’ review on psychiatric disorders. As the focus was on emerging data for the use of mental health disorders, we omitted addiction and neurological disorders, which have been extensively covered elsewhere [10, 19], cf. pain [20,21,22], cf. epilepsy [23, 24], cf. movement disorders [25]. A further motive for this paper focusing solely on psychiatric disorders, concerns cannabis users noting that self-reported anxiety, insomnia, and depression symptoms are amongst the most common reasons for usage [26].

Thus, the primary purpose of this paper is to provide a systematic review of the current state of evidence in the emerging field of cannabinoid therapies for psychiatric disorders (PTSD, generalised anxiety disorder, social anxiety, insomnia, psychotic disorders, and attention-deficit hyperactivity disorder: ADHD). In addition, this review provides clinical prescriptive guidelines and consideration of both safety and occupational public health issues. We also provide discussion on considerations for future research in the field. Our intention was to provide a review of the extant literature to inform a discussion with clinical context and appropriate recommendations.

Methods

Due to the field still being in its infancy, a broad inclusion criteria was applied to the available data. The purpose was to locate human studies involving whole cannabis plant medicines and cannabis-derived isolates (singularly or in combinations) for the treatment of major psychiatric disorders or mental health symptoms. Synthetic cannabinoid analogues (e.g. nabilone) and THC isomers (e.g. dronabinol) were omitted as these fall under the auspices of a pharmaceutical-focused review (as these are classified as pharmaceutical ‘drugs’).

Major electronic databases including OVID MEDLINE, Cochrane Central Register of Controlled Trials, Health Technology Assessment Database, Allied and Complementary Medicine and PsychINFO were accessed for data up to July 2019. Initially, data were sought for meta-analytic or systematic review level epidemiological evidence (as there is sufficient data available) on the cross-sectional or longitudinal association of cannabis use and individual psychiatric disorders or symptoms. This was undertaken to assess any deleterious relationship between cannabis and psychiatric disorders. We then specifically sought any literature involving interventional human trials and observational studies, including case studies (due to deficient randomised controlled trials [RCTs] in this emerging area). We included studies with any sample size or age or gender, which used either inhalant, oral, or transdermal administration of medicinal cannabis or cannabis-derived isolates. All studies in English were assessed for inclusion (see supplementary data for the PRISMA flow chart for the number of human clinical trials or case studies excluded/included). The results are presented to firstly cover the major current epidemiological evidence, and then next all available clinical trial or case study data.

The following search terms were used to locate human studies or case report publications:

TITLE: cannab* OR THC OR tetrahydrocannabinol OR canab*

TITLE: depression or depressive or mental illness* or mental disorder* or mental health or mood disorder* or affective disorder* or anxi* or panic disorder or obsessive compulsive or adhd or attention deficit or phobi* or bipolar or psychiat* or psychological or psychosis or psychotic or schizophr* severe mental* or serious mental* or antidepress* or antipsychotic* or post traumatic* or personality disorder* or stress

In summation, 481 articles were located, which was reduced to 310 after duplicates were removed. Of these, 13 studies fitted the eligibility criteria as clinical studies of cannabis-based treatments for symptoms of psychiatric disorders. The full search and screening process is displayed in the supplementary data. There were insufficient homogenous studies to perform a meta-analysis.

Affective disorders

Anxiety

The endocannabinoid system has been found to be a modulator of anxiety and mood, with recent data showing that cannabinoids or substances which target this system may interact with specific brain regions, including the medial prefrontal cortex, amygdaloid complex, bed nucleus of stria terminalis, and hippocampus [27]. Interaction with the CB1 receptor has a modulating effect on GABAergic and Glutamatergic transmission [28], while also influencing the hypothalamic pituitary adrenal (HPA) axis, immune system activation, and neuroplastic mechanisms. In respect to specific psychotropic mechanisms of action, the anxiolytic (and antidepressant effects) may also in part be mediated via CBD’s serotonergic effects via 5-HT1A receptor activation [29], and THC’s CB1 receptor agonism [30, 31]. It is worth noting that studies have demonstrated that CBD may partially inhibit the psychoactive effects of THC, with CBD and THC having demonstrated differing symptomatic and behavioural effects on regional brain function [32,33,34,35].

As in the case of certain other psychiatric symptoms and disorders, epidemiological evidence indicates that there is a relationship between cannabis use and anxiety symptom levels. This association (assessed by Kelzior and colleagues [36] via meta-analysis of 31 studies) has to date only been found to be weak, and based largely on cross-sectional data. Thus, it may be that those with anxiety seek cannabis treatment, rather than a causal effect occurring from cannabis use. Longitudinal data is also not convincing due to the bias of one study with a large odds ratio included in their meta-analysis. However, a stronger positive association was revealed between anxiety and cannabis use disorder. Other longitudinal data involving the USA-based National Epidemiologic survey on Alcohol and Related Conditions [37] confirms there is no obvious causal inference. The study included individuals with a diagnosis of any anxiety disorder during the initial 4-year data collection period, comparing cannabis nonusers to users, and also individuals with cannabis use disorder at a later time point on a range of psychosocial measures. Results revealed that, when controlling for baseline confounders, no significant relationship was found with cannabis use and a greater frequency of anxiety.

While to date no human trials could be located for treatment of Generalised Anxiety Disorder using whole cannabis plant extracts or combined isolates, there was one study identified testing CBD (Table 1) for Social Anxiety Disorder. One small preliminary double-blind RCT compared the effects of a simulated public speaking test on treatment-naïve patients with social anxiety (n = 24) versus healthy control participants (n = 12) [38]. Each group received a single acute oral dose of CBD (600 mg) 1.5 h before the test, or matching placebo. Results revealed that pre-treatment with CBD significantly reduced anxiety, cognitive impairment and discomfort in the social anxiety group’s speech performance, and significantly decreased hyper-alertness in their anticipatory speech compared to the placebo group (which presented higher anxiety, cognitive impairment, discomfort, and higher alertness levels). Neuroimaging research has also revealed that in individuals diagnosed with social anxiety, cerebral blood flow may be altered via CBD. One study employed fMRI in 10 treatment-naïve patients with social anxiety who were given 400 mg of oral CBD or placebo in a double-blinded crossover manner. Relative to placebo, 400 mg of CBD was associated with significantly decreased subjective anxiety, with blood flow being modulated in the left parahippocampal gyrus, hippocampus, and inferior temporal gyrus, and the right posterior cingulate gyrus [39]. This suggests that CBD’s activity may occur via interaction with the limbic and paralimbic brain areas.

Due to the small sample sizes, the above data needs to be considered with caution. Further, appropriate and considered treatment of anxiety disorders with cannabinoid therapies is crucial due to the complex relationship with substance use disorders, often requiring a more complex biopsychosocial approach [40]. With this context in mind, CBD (being a non-intoxicant compared to THC) may be a more preferable option, having also shown anxiolytic effects in preclinical studies [41].

In respect to planned or ongoing research, one study in Colorado USA has just commenced and is exploring the anxiolytic effects of vaporised or ingested THC/CBD in differing ratios (1:0, 1:1, 0:1) in people with mild-moderate anxiety [42]. Another study is assessing the effect of CBD on reducing symptoms of anxiety disorders in a youth cohort (12–25 years old). The Australian-based study is a 12-week open-label pilot, which aims to see if 200 mg–800 mg of oral CBD (titrated depending on age, tolerability, and efficacy) is safe and effective for a youth population [43].

Post-traumatic stress disorder (PTSD)

Whole plant cannabis use for the management of PTSD symptoms has been identified in usage analyses [44], and in particular in returned armed services veterans [45]. The proposed neurobiological mechanisms by which medicinal cannabis may assist with PTSD are varied and mostly derived from animal research. There are high concentrations of endocannabinoid receptors in the prefrontal cortex, amygdala and hippocampus [46], having a role in fear acquisition and extinction [47]. There is strong evidence revealing that a disruption of the endocannabinoid system impairs fear extinction in CB1 knockout mice, suggestive of a critical role of CB1 receptors (and thereby potentially THC) being related to the extinction of fear [48,49,50].

One survey involving a convenience sample of 170 patients via a medical cannabis dispensary in California evaluated a range of health elements, the frequency of cannabis use, and general mental health [51]. Results revealed that those with high PTSD scores (assessed via The PTSD Checklist-Civilian Version) were more likely to use cannabis to assist with mental health coping, in addition to improving sleep, when compared with those with low PTSD scores. In particular, cannabis use frequency was greater among those with high PTSD scores who often used this for improving sleep. While there is increased use of cannabis in those with PTSD, there is currently no firmly supportive epidemiological data. A cross-sectional case control study of veterans showed that regular users do not have lower PTSD symptoms than non-users [52].

A recent open label retrospective analysis of case study data from 11 adults with PTSD assessed the patients over 8 weeks of CBD treatment (capsule or spray; mean dosage at week-8 of 49 mg) [53]. Results revealed that a reduction in mean PTSD symptoms occurred in 28% of the sample, as assessed on the PTSD checklist for DSM-5 (PCL-5). Statistical data analysis was not conducted, however, and thereby it is not possible to draw firm conclusions. Another retrospective study analysing PTSD symptoms collected during 80 psychiatric evaluations of patients applying to the New Mexico Medical Cannabis Program during 2009 to 2011 [54], revealed more supportive findings. The data identified a greater than 75% reduction in Clinician Administered Posttraumatic Scale for DSM-IV (CAPS) symptom scores when patients with PTSD were using cannabis compared to when they were not. While this study had a small sample, and is a retrospective analysis that has some methodological weaknesses, a 75% reduction on the CAPS is a compelling result, and has spurred recent RCTs which are currently in recruitment [55, 56].

Depression

Phytocannabinoids and terpenes have a potential application for modulation of the endocannabinoid system and the 5HT1A receptor to provide an antidepressant effect [16]. No RCTs to date have been conducted on the primary outcome of depression. Three studies assessing oral-administered nabiximols (i.e. botanically derived preparation containing standardised levels of THC, CBD, terpenes and flavonoids from cannabis) for other conditions (multiple sclerosis and cannabis withdrawal) found no significant effect on the secondary outcome of depression [57,58,59]. It is worth noting that one study involving cancer patients using nabiximols showed a significant reduction in mood occurred for those who used the highest dose (11–16 sprays per day) compared to the placebo [60]. Further, some epidemiological evidence has revealed a greater level of depressive symptoms in heavy cannabis users compared to light-users and non-users [61]. Due to this, higher dose THC should be avoided in people with major depressive disorder (MDD) or low mood. However, a cross-sectional survey on patterns of use and perceived efficacy suggested that in over 1429 participants identified as medical cannabis users, over 50% reported using medicinal cannabis specifically for depression [62].

Insomnia

Anecdotal survey evidence abounds for the soporific effect of cannabis, with sufferers of a range of conditions including pain, anxiety and PTSD reporting that it assists in the management of insomnia [51, 63,64,65,66,67,68]. While this may commonly take the form of whole plant cannabis being administered via vaporised inhalation, isolated CBD may also be of benefit. An example case study detailed in the literature concerns a 10-year-old girl with prior early childhood trauma [69]. A trial of oral CBD oil (25 mg) resulted in a decrease in this patient’s anxiety, and improvement in the quality and quantity of her sleep. A more substantial retrospective case series of 72 adults given CBD for anxiety and sleep complaints at a psychiatric clinic (as an adjunct to usual treatment) assessed patient data monthly over 12 weeks [70]. Anxiety scores on the Hamilton Anxiety rating Scale (HAMA) decreased within the first month in 79% of the sample and remained low during the study duration. The Pittsburgh Sleep Quality Index score also improved within the first month in 67% of the sample, but fluctuated over time. It should be noted that the data were not analysed for statistical significance, and it appeared that the sub-sample presenting primarily for anxiety treatment did not fare as well as the cohort presenting primarily with sleep issues.

See also  Cbd oil for pigmentation

A study by Johnson et al. [71] tested the long-term safety and tolerability of a THC/CBD spray and a THC spray in relieving pain in patients with advanced cancer. A total of 43 patients were continued on a previous three-arm RCT involving an open label administration of a self-titrated THC/CBD spray (n = 39) or THC spray (n = 4) (2.7 mg) assessed over a 5-week period. While results revealed a consistent reduction in perceived pain, participants also reported a decrease in their insomnia, which also reflected less fatigue. Cannabinoids may have a dual effect of lessening pain (which makes it easier to sleep), in addition to their direct soporific and anxiolytic effects being mediated in part via serotonergic activity.

As detailed above, the evidence for this use is currently very weak, and to date no RCTs were located in the literature specifically assessing cannabinoid isolates or whole plant formulas. As of late 2018, there is however, a clinical trial taking place in Australia assessing cannabinoid treatment in chronic insomnia [72]. The study, based in Western Australia, is aiming to enrol 24 participants aged (25–70 years) who have insomnia (defined as difficulty initiating or maintaining sleep for 3 or more nights per week for at least 3 months). The intervention involves an oral MC extract (ZTL-101) or placebo given in a cross-over manner for a study period of approximately 2 months. Participants will be assessed via the clinically-validated insomnia scales, an actigraph watch, and will be assessed in a sleep centre after 2-weeks.

Psychotic disorders

Schizophrenia

Consistent evidence has shown that there is a relationship between schizophrenia and cannabis use [73,74,75]. Heavy cannabis use may proceed to a diagnosis of the disorder, however, increased use may also result from ‘self-medication’. Cannabis use is cross-sectionally associated with more severe symptoms of psychosis in young people who do not meet the threshold for schizophrenia, and appears to be one high-risk component for the tumescence of the disorder [76]. More importantly, there is also longitudinal data to support a causal relationship [77,78,79]. A 2016 meta-analysis showed that while general lifetime use is not cross-sectionally associated with increased risk of psychosis, there is a robust relationship demonstrated in recent or current use in ultra-high-risk (UHR) adolescents with a DSM-diagnosed cannabis use disorder [80]. A recent prominent study has corroborated this finding. Data from 11 sites across Europe and Brazil involving patients with first-episode psychosis versus population controls, revealed that daily cannabis use was associated with increased odds of a psychotic disorder occurring compared with never-users, with nearly five-times increased odds for daily use of high-potency THC types of cannabis [81]. Several academics [82,83,84,85,86] have disputed these findings and comment that while there is a relationship, cannabis use is not causally related to increased psychosis risk (potentially due to a range of confounders e.g. correlated genetic liabilities or indirect and bidirectional processes). However, di Forti and colleagues (the study authors) [87] maintain that the data does indeed support this causal association, and that other research has flawed elements (e.g. previous Mendelian Randomisation studies using imprecise measurements of cannabis use).

It is of note that schizophrenia risk alleles are linked to cannabis use in a general population [78]. Regardless, the transition rates from a general population of cannabis users to schizophrenia is very low and can be considered to be part of a constellation of various potential gene-environment interactions. Several key genes have been implicated as potentially modulating the risk of developing schizophrenia after early cannabis use: BDNF, CNR1, COMT, AKT1, and DRD2 genes [88, 89]. There is also a likely increased susceptibility when a combination of these at-risk alleles from these single nucleotide polymorphisms (SNPs) are combined with childhood trauma [90, 91].

The apprehension regarding the promotion of psychotic symptoms are primarily based on the THC constituent of cannabis, a CB1 receptor agonist, which is the primary psychoactive phytochemical. This effect has been shown to be more prominent in users of high-THC cannabis, or in chronic heavy users [92]. Thus, THC should be avoided in people with or at risk of schizophrenia. Exposure to THC increases extracellular dopamine and glutamate and decreases GABA concentrations in the prefrontal cortex [93]. A recent double-blind crossover RCT investigated whether altered striatal glutamate (measured via proton magnetic resonance spectroscopy) was a mediating biomarker from intravenously administered THC in 16 healthy participants [94]. Results revealed that that an increase in striatal glutamate levels may underlie acute cannabis-induced psychosis, while lower baseline levels may provide a valid biomarker of greater sensitivity to its acute psychotomimetic effects.

The psychotropic effects of THC may mimic the presentation of psychotic symptoms, including paranoia, sensory alteration, euphoria, and hallucinations [95]. In laboratory-based research, people with schizophrenia appear to be even more sensitive to the psychosis-inducing effects of THC than healthy controls [96]. In contrast to THC, as mentioned in the introduction, CBD may in fact provide an opposing effect to THC albeit more research into this mechanism is required. Additional effects include the inhibition of anandamide breakdown via fatty acid amide hydrolase (FAAH) blocking effects, and anti-inflammatory effects [97, 98].

CBD is well-tolerated with minimal deleterious psychoactive effects (although some psychological effects are evident due to modulation of the 5HT1A receptor and enhanced anandamide signalling) [99]. Due to this, studies have primarily employed isolated CBD, however this work could potentially be extended to formulas from whole-plant strains which are high in CBD (> 10 mg/g) and lower in THC (< 4 mg/g). These preparations may also contain other yet-to-be-studied compounds from the plant which may be beneficial for the positive or negative symptoms of schizophrenia.

In respect to current research, aside from an initial index case study conducted by Zuardi, Morais [100] in 1995, who showed that 1500 mg of CBD administered for 26 days was beneficial for treatment-resistant schizophrenia, three clinical studies exist to date. A study by Leweke, Piomelli [99] tested in a double-blind, RCT design 600–800 mg/day of oral CBD vs the antipsychotic amisulpride over 4 weeks in 42 patients. While both treatments were safe and led to significant non-differential clinical improvements, the CBD arm had a superior side-effect profile. CBD also significantly increased anandamide levels, which was associated with clinical improvement. Another double-blind parallel-group trial, involving 88 patients with schizophrenia who were given either oral CBD (1000 mg/day) or placebo adjunctively to existing antipsychotic medication revealed after 6 weeks of treatment that the CBD group had lower levels of positive psychotic symptoms on the Positive and Negative Syndrome Scale (PANSS), and were more likely to have been rated as improved via clinician-ratings [101]. While these studies were supportive of CBD, a recent double-blind RCT by Boggs, Surti [102] found no benefit for 600 mg/day of CBD in comparison to placebo. The 6-week study involving 36 patients with schizophrenia revealed that both placebo and CBD PANSS scores improved, but no Group × Time effect was evident. The CBD was well-tolerated, however, and more sedation was evident in the CBD group compared to placebo.

Furthermore, CBD may confer some protective effects in young people at clinical high-risk for psychosis (n = 33), as a recent single-dose RCT found that 600 mg of CBD temporarily normalised aberrant brain activity in the parahippocampal, striatal, and midbrain areas, which is associated with increased psychosis risk [103]. Currently, an ongoing clinical trial in the United Kingdom is assessing the efficacy of 600 mg of CBD per day for reducing symptoms of psychosis in young people at clinical high-risk for psychosis [104].

Bipolar disorder

To date no clinical trial has assessed cannabinoids for the treatment of bipolar disorder (in respect to maintaining euthymia, or as a treatment of hypo/mania or depression), although there is a potential role of the endocannabinoid system in the disorder, as detailed above. Initial case reports contend this approach may not however be of benefit [105]. Two patients diagnosed with DSM-IV Bipolar type I disorder, and presenting with mania, were provided adjunctive CBD (titrated to 1200 mg per day) after receiving placebo for an initial five-day period. On Day 31, CBD treatment was discontinued and replaced by placebo for five days. While the first patient showed symptom improvement while on olanzapine plus CBD, she showed no additional improvement during CBD monotherapy, while the second patient had no symptom improvement with any dose of CBD during the trial. Both patients tolerated CBD very well and no side-effects were reported, despite no obvious effect on reducing mania.

Evidence has revealed that adults with ADHD may self-medicate with cannabis as a coping strategy for a range of potential effects [106]. Off-label use in the US for this application has been noted despite a relative deficit of evidence for this use [107]. One study was located, the “Experimental Medicine in ADHD-Cannabinoids” pilot RCT, using nabiximol (cannabinoid/terpene combination) oromucosal spray in 30 adults with ADHD for 6 weeks [108]. The primary outcome was cognitive performance and activity level (as measured by head movements) using the Quantitative Behavioural Test. Secondary outcomes included ADHD and emotional lability symptoms. While a trend towards significance occurred in favour of nabiximols, no significant difference was revealed on the primary outcomes. Notably, the use of nabiximols did not impair cognition. For secondary outcomes, the combination of note was associated with a nominally significant improvement in hyperactivity/impulsivity scores on the investigator-rated Conners Adult ADHD Rating Scale. The combination was well-tolerated, however, a serious adverse event involving muscular seizures/spasms occurred in the active group. While not definitive, this study provides preliminary evidence supporting the self-medication theory of cannabis use in ADHD and the need for further studies of the endocannabinoid system in ADHD. Results, however, did not meet significance following adjustment for multiple testing, and it should be recognised that the sample size was small, thus a more robust sample would be better placed to determine the true effect.

Discussion

Data synthesis

As the present data indicates, the current field of cannabinoid therapeutics in psychiatry currently provides no convincing evidentiary support for use in any mental health application. More research is urgently needed, and many RCTs are currently being undertaken; thereby the landscape will change rapidly over the next several years. Currently, the most promising (although inconclusive) evidence is for CBD as an adjunctive treatment in schizophrenia, with an additional isolated study showing efficacy in social anxiety, and weak data suggesting a potential effect for ADHD symptoms. The evidence also tentatively suggests that a role exists for cannabinoids in PTSD, and also in reducing insomnia, which may also commonly occur in chronic pain. For other plant-derived cannabinoid therapy applications for psychiatric symptoms/disorders (e.g. several affective disorders) no firm conclusions can currently be drawn.

Clinical prescriptive considerations

It initially should be recognised by clinicians that, as detailed above, weak evidence currently exists in the field, thus this prescriptive advice should be taken in the context of evolving research. The first consideration faced by a clinician (in a legal jurisdiction) with a patient who is interested (or for clinician-initiated prescription) in using cannabis medicinally, is whether this is medically appropriate for them. A thorough screening firstly needs to occur, with Canadian British Columbian Physician guidelines [109] suggesting that clinicians initially assess:

Age – higher-dose THC forms not advised in people < 25 years of age;

If a personal history or family history of psychosis is present, and if so, no THC is advised;

Any current or past drug or alcohol misuse or dependence (avoid especially in individuals with cannabis dependence or misuse);

Cardiovascular or respiratory diseases (avoid or use caution);

Current medications which may interact with cannabis; and

Pregnant or planning or conceive or breastfeeding (avoid).

Next, if no contraindication is apparent, medical consideration can be given to what potential clinical application the MC may present for, and the cannabis formulation or isolate/s that may be appropriate for them. Given the complexity of MC whole-plant formulas (and the current challenge to standardise for batch-to-batch consistency), companies have primarily tested cannabinoid isolates and analogues. The most studied including nabiximols (Sativex), nabilone (Cesamet), and dronabinol (Marinol). While this may provide more pharmacological assurity, such an approach also negates the potential of unique genetic chemovars of cannabis which may provide specific therapeutic activity due to a complex synergistic interaction of constituents (known as the entourage effect). Patient preference may also be towards vaporisation of dried raw material [110]. To this end, specific prescriptive considerations need to be adopted, including:

Determining patient preference regarding administration – vaporisation (via specific devices), inhalation via traditional smoking apparatuses, oral dose (i.e. capsule, oil or in some cases food product), sublingual via lozenges or sprays. Note that each has a different onset of action and half-life. Inhalants will provide a more instantaneous effect (due to the alacrity of THC decarboxylation), whereas oral forms will take longer e.g. 45–90 min to take effect. Both forms of administration may be advisable to provide flexible symptom management;

Patient’s personality in terms of the effects of higher THC formulas. Avoidance of higher THC formulas should occur in youth and in those with paranoid personalities;

Potential for abuse (with greater theoretical potential in vaporised/inhaled forms [which also carries additional general health consequences]);

When the application should occur with respect to occupational and carer responsibilities and driving. Note that there is the potential to prescribe different cannabis preparations which contain differing levels of THC and CBD, with higher dose THC applications being applied preferentially in the evening.

CBD dosage (based on current evidence) varies according to disorder, age, weight, and potentially pharmacogenetic differences. Most research tends to focus on a range of 200 mg–800 mg per day [111]. In respect to THC-containing formulas, it has been advised to be cautious exceeding 20 mg per day due to potential side effects [112], and people may find a psychotropic effect with as little as 1 mg–2.5 mg per dose.

As mentioned above, there are a myriad of potential cannabis chemovars that can be developed, each with unique medicinal applications. However, to maintain pharmacodynamic/kinetic consistency, at present, the two major constituents commonly standardised for are THC and CBD (in some cases select terpenes are also included). THC provides, as indicated above, the primary psychotropic effect, and higher doses may be preferable for the amelioration of pain and inducement of sleep [63]. Further, it may provide an acute mood elevating effect in some people, however as mentioned, this may also elicit symptoms of paranoia, anxiety, and cognitive impairment (and in higher doses may actually impair mood). This effect may potentially be opposed by CBD (and/or other less studied cannabinoids), however data is mixed as to this effect. Additionally, the findings are not clear cut, with users of cannabis (to treat anxiety) having a statistically significant preference for higher THC/lower CBD containing cannabis cultivars [113].

Safety considerations

Clinicians needs to be aware that cannabinoid therapies may elicit a range of side effects. In respect to potentially expected side-effects from cannabinoid interventions, occasional adverse effects revealed in clinical trials include co-ordination problems, dizziness, disorientation, euphoria, drowsiness or fatigue, dry mouth, nausea and gastrointestinal upsets [10]. Due to this, regular monitoring is advised, especially when commencing treatment in cannabis-naïve patients.

The previously cited report conducted by the National Academy of Sciences [6] on the health effects of cannabis and cannabinoids cites limited evidence that cannabis use increases the rates of initiation of other psychoactive drugs. Additionally, while there are concerns over the relationship with schizophrenia, no firm evidence shows any association between cannabis use and the likelihood of developing bipolar disorder. Further evidence is suggestive that smoking cannabis on a regular basis is associated with cough and phlegm production, while limited evidence exists suggestive of a statistical association between cannabis use and ischaemic stroke and/or acute myocardial infarction. Evidence is noted to exist for the association between increased cannabis use frequency and progression to developing problematic cannabis use [6], as well as potential respiratory infections/disorders (especially in the use of poor-quality raw material). Clinicians need to balance these concerns together with the potential benefits, especially regarding the potential for lesser harm from other prescriptive or illicit options in patients managing psychiatric and pain conditions.

Pharmacogenetic considerations

Increased attention to the influence of pharmacogenetics factors is advised, with several genes being identified that may differentially affect cannabinoid pharmacokinetics and pharmacodynamics. A recent review led by Hryhorowicz [114] characterised pertinent genes with relevant interaction with cannabis into three broad categories: Receptor genes (CNR1, CNR2, TRPV1, and GPR55), transporter genes (ABCB1, ABCG2, SLC6A) and pharmacokinetic/metabolism (CYP3A4, CYP2C19, CYP2C9, CYP2A6, CYP1A1, COMT, FAAH, COX2, ABHD6, ABHD12). Research into the pharmacogenomic influence is however nascent, with most of the focus being on the relationship with cannabis dependence (e.g. CNR1 receptor SNPs which shows no obvious association), or schizophrenia (COMT, DRD2 SNPs showing a stronger correlation) [81, 114]. Further exploration of FAAH SNPs differentially affecting people’s response to CBD is also of value (given its important role in inhibiting the degradation of anandamide).

Occupational and public health considerations

Occupational health and safety issues also exist in consideration with medicinal cannabis users. Workplace safety concerns have been raised in relation to the potential for medicinal cannabis use to impair judgement and psychomotor skills, especially in relation to motor vehicle use, operation of fixed and mobile plants particularly heavy industrial machinery, and the potential for risk-taking behaviors and those working in safety sensitive positions [115, 116]. Employers have a ‘duty of care’ to provide safe and healthy workplaces, which includes the management of alcohol and drug use and their potential to create unsafe workplaces or practices. Workplace drug testing (WDT) is common in some industries including mining, transportation and correctional services [117]. Employees in building, transportation, maritime and mining operations cannot use drugs, legal or illegal, if they could impair their ability to safely undertake their duties [118]. However, the presence of a drug, or its metabolite, in a person’s system is not always proportional to cognitive impairment [119]. In addition, WDT does not discriminate between recreational or medicinal use and could place medicinal cannabis patients at risk of discrimination or unfair dismissal. Implementation of WDT should be balanced with a greater knowledge on the dose response relationship between cannabis-based medicines and their potential side effects.

See also  Doterra cbd oil for pain

Medicinal cannabis patients may also be subject to mobile drug testing in jurisdictions such as Australia. The salivary testing process is inefficient for assessment of cannabis related driving impairment because the tests can trace THC in saliva for days after consumption, long after any cognitive impairment has abated. The potential impact of medicinal cannabis on function will vary with dose, the length of usage (tolerance), route of administration (oral versus smoking), [120] and saliva THC levels are not direct measures of cognitive status. Further, the concentration of THC in urine does not correlate with cognitive function [120]. Conversely, in the US, a whole blood THC level of 5 ng/mL has been established as a legal limit for driving in states where cannabis has been legalised [121]. Guidelines and strategies for the specific risk management of cannabis in the workplace have been published in North America [120,121,122,123]. However, Australia is yet to publish its own risk management guidelines relating to medicinal cannabis in the workplace, although generic workplace alcohol and drug risk management guidelines could be adapted in the interim [118].

Future research considerations

While research is rapidly advancing, there is a challenge regarding the adequate blinding of medicinal cannabis studies (due to the obvious psychotropic effect, and lack thereof in cannabinoid-removed controls) [124]. This may be addressed via cannabis naïve participants with psychomimetic controls (e.g. atropine; these however have the innate challenges of being biologically active themselves); adequate assessment of un/blinding; and use of varying levels of THC within the study. It still should, however, be taken in the context of other psychiatric or neurological research, with opioids and benzodiazepines also eliciting an obvious psychophysiological effect, and the acceptance of the research demonstrating analgesic and anxiolytic effects, respectively.

Conclusions

Currently the evidence is nascent and too weak to recommend cannabinoid-based interventions for a range of psychiatric disorders. While encouraging, research is only just beginning to determine whether cannabis or its isolates may or may not be effective for this application, and clinicians need to be mindful of several safety considerations (as articulated above). The most promising (although inconclusive) evidence is for CBD as an adjunctive treatment in schizophrenia, with an additional isolated study showing efficacy in social anxiety, and some data suggesting a potential effect for PTSD and ADHD symptoms. The data also tentatively suggests that a role exists for cannabinoids in reducing insomnia, which may also commonly occur in chronic pain. Given the generally favorable safety profile of cannabinoids observed across the observational studies and clinical trials conducted to date, there is clearly a strong case for encouraging further research.

New Research Reveals Why Cannabis Helps PTSD Sufferers

Amy Rising, an Air Force veteran, smokes medical marijuana. Rising has been working on legislation . [+] for veterans’ freedom to treat PTSD with medical cannabis. (Photo by Kevin Cook for The Washington Post via Getty Images)

The Washington Post via Getty Images

PTSD patients have been saying for years that cannabis helps with their PTSD. This debilitating condition causes chronic problems like nightmares, panic attacks, hypervigilance, detachment from others, overwhelming emotions, and self-destructive behavior. In some cases, these overwhelming symptoms can even lead to suicide. And while research on the topic has been somewhat inconclusive, many PTSD patients continue to report that cannabis does help.

Now, new research suggests the biological mechanisms behind this therapeutic effect.

Two recent studies point to the way that cannabinoids may help treat PTSD. One shows how cannabis can reduce activity in the amygdala – a part of the brain associated with fear responses to threats. Meanwhile, another suggests that the plant’s cannabinoids could play a role in extinguishing traumatic memories. Both effects could be therapeutic for those suffering from PTSD – according to recent studies.

One study, from researchers at Wayne State University in Detroit, MI, looked at how cannabis use impacts the amygdala response of those dealing with trauma related anxiety, such as PTSD. Previous research has shown that cannabis has the potential to reduce anxiety, or even prevent heightened anxiety in threatening situations. But up to this point, no studies had investigated this response in adults dealing with trauma – such as those with PTSD.

The Wayne State University study took on this challenge, and studied the amygdala responses in three groups of participants – healthy controls who had not been exposed to trauma, trauma exposed adults without PTSD and trauma exposed adults with PTSD. Using a randomized, double-blind procedure, the 71 participants were either given a low dose of THC or a placebo. Then they were exposed to threatening stimuli and their amygdala responses were recorded.

Best Travel Insurance Companies

Best Covid-19 Travel Insurance Plans

Those exposed to THC had lowered threat-related amygdala reactivity.

This means that those who took low doses of THC showed measurable signs of reduced fear and anxiety in situations designed to trigger fear. Since these results were found in all three groups, it suggests that even those with PTSD were able to experience less fear with THC in their system.

DENVER, CO – JULY 15: The Colorado Board of Health had a rule making hearing about people with . [+] PTSD qualifying for medical marijuana at the Colorado Department of Public Health and Environment offices in Denver. Christopher Latona, center, and his dad Mike Latona, left, both testified in support of approving medical marijuana for PTSD which Christopher has suffered from since returning from his US. Army service in Afghanistan. They were photographed on Wednesday July 15, 2015. The board voted 6-2 not to approve the change. (Photo by Cyrus McCrimmon/The Denver Post via Getty Images )

Denver Post via Getty Images

The authors conclude that the research suggests “that THC modulates threat-related processing in trauma-exposed individuals with PTSD” and add that the drug “may prove advantageous as a pharmacological approach to treating stress- and trauma-related psychopathology.”

A second study, from researchers at Brazil’s Federal University of Parana, explored another potential way that cannabis could help those with PTSD – extinguishing the intensity associated with memories of their trauma. This mode of treating PTSD was first hypothesized by Yale associate professor of psychiatry R. Andrew Sewell who suggested that cannabis may be able to help PTSD patients “overwrite” traumatic memories with new memories in a process called ‘extinction learning’.

In an interview with East Bay Express, Sewell explained that the extinction learning process usually helps trauma resolve on its own. He gave the example of an Iraq War Veteran who gets PTSD symptoms while driving under bridges – after dodging explosives thrown down from bridges during the war. “Suppose some part of your reptile brain thinks if you walk under a bridge you’re going to die,” Sewell explained “life becomes very hard.”

Army veteran Kevin Grimsinger 42 and other vet’s and supporters from Sensible Colorado submit a . [+] petition to add PTSD to the list of conditions approved for the use of medical marijuana to Mark Salley the communications director for the Colorado Department of Public Health and Environment Wednesday July 7th, 2010. Joe Amon, The Denver Post (Photo By Joe Amon/The Denver Post via Getty Images)

Denver Post via Getty Images

For most who experience traumatic incidents, these fears subside after 6 months or so because of the extinction learning process. New memories of the traumatic trigger form and override the old. Someone with a traumatic experience of explosives being dropped from bridges, may at first feel terrified as they approach any bridge – with traumatic memories flooding their mind. But after months of nothing bad happening around bridges, most will begin to feel bridges are less dangerous, as many memories of driving under bridges safely accumulate. The old memories still linger, but they don’t cause the increase in fear when the trigger (like the bridge) is present. So while most with trauma remember the traumatic incidents, those memories no longer trigger intense fear.

But for those with PTSD, extinction learning doesn’t happen. The trauma attached to the old memories continues to cause problems.

Still, Sewell believed that cannabis could help. Cannabis stimulates CB1 – a receptor in the endocannabinoid system that Sewell says has improved extinction learning in animal studies. Interestingly, those with PTSD show impaired functioning of the endocannabinoid system – which may be why they are unable to go through the normal extinction learning process.

Sewell theorized that cannabis might be able to jump start this process – allowing those with PTSD to access extinction learning like their healthy counterparts, and curing the PTSD by helping them to move on from their trauma. Unfortunately, he was unable to complete his research before he unexpectedly passed away in 2013.

study from Brazil’s Federal University of Parana looks deeper into the question. These researchers conducted a thorough review of the cannabis literature from 1974-2020 looking for evidence from controlled human trials to support or refute the theory that cannabis helps with ‘extinction’ of traumatic memories.

The researchers found that cannabis could help. Low doses of the cannabinoid THC or THC combined with another cannabinoid CBD were both able to enhance the extinction rate for challenging memories – and reduce overall anxiety responses. From their study, it seems that THC drives the extinction rate improvements, while CBD can help alleviate potential side effects from higher doses of THC.

The authors conclude that the current evidence from both healthy humans and PTSD patients suggests that these forms of cannabis “suppress anxiety and aversive memory expression without producing significant adverse effects.”

These studies provide some answers about why cannabis is helping PTSD patients feel better – both immediately and in the long run. Still, future studies may help clarify a range of questions about how and when to use cannabis effectively for PTSD, and whether there are risk factors associated with using the drug for this condition.

The Use of Medicinal Marijuana for Posttraumatic Stress Disorder: A Review of the Current Literature

Corresponding author: Stephanie Yarnell, MD, PhD, Department of Psychiatry, Yale University, 300 George St, Ste 901, New Haven, CT 06510 ([email protected]).

Abstract

Background:

Medicinal marijuana has already been legalized in over 23 states with more considering legalization. Despite the trend toward legalization, to date, there has been no systematic review of the existing literature for the efficacy of medicinal marijuana for many of the conditions for which it is proposed to treat. This study seeks to understand the current literature regarding the use of medicinal marijuana in the treatment of posttraumatic stress disorder (PTSD).

Data Sources:

PubMed and PsycINFO databases were searched until April 2014 for articles outlining outcomes of case files, control studies, and observational studies regarding the efficacy of medicinal marijuana in treating PTSD. Various combinations of the following search terms were used: marijuana, medicinal marijuana, cannabis, cannabinoid, PTSD, efficacy, trial, and neurobiology.

Study Selection:

Full text of each article was reviewed, and those directly addressing the question of efficacy of medicinal marijuana on PTSD symptomatology were included. Data were extracted from a total of 46 articles.

Results:

Analysis revealed that most reports are correlational and observational in basis with a notable lack of randomized, controlled studies. Many of the published studies suggest a decrease in PTSD symptoms with marijuana use. Though the directionality of cannabis use and PTSD could not be fully differentiated at this time, there appears to also be a correlation between PTSD and problematic cannabis use. Despite this finding, there is a growing amount of neurobiological evidence and animal studies suggesting potential neurologically based reasons for the reported efficacy.

Conclusions:

Posttraumatic stress disorder is 1 of the approved conditions for medicinal marijuana in some states. While the literature to date is suggestive of a potential decrease in PTSD symptomatology with the use of medicinal marijuana, there is a notable lack of large-scale trials, making any final conclusions difficult to confirm at this time.

Clinical Points

■ Posttraumatic stress disorder (PTSD) is one of the approved conditions for medical marijuana in some states.

■ Current literature is suggestive of a potential decrease in PTSD symptomatology with medical marijuana, but also suggests a correlation with problematic cannabis use, though directionality is not established at this time.

■ Neurobiological studies in both humans and animal models are providing further insights into the reported efficacy of medical marijuana for PTSD.

■ Lack of large-scale randomized controlled trials makes any final conclusions difficult.

Cannabis is currently the most widely used illicit substance, with approximately 18.1 million people reporting use within a 1-month period in 2011 within the United States alone. 1 The rapidly changing legal environment surrounding cannabis, both for medicinal and recreational use, is becoming increasingly relevant to patient care. While still illegal under federal law, at least 23 states have approved marijuana for medical use, and recreational use is now legal in Colorado and Washington. The approval of marijuana as a purported medication is unique, as it is done under state authority, either by ballot or by state legislature approval, without approval of the US Food and Drug Administration (FDA). Whereas the FDA requires multiple rigorous clinical trials evaluating safety and efficacy prior to the approval of a drug for a specific indication, there are no standard requirements for state approval of indications for medical marijuana. In at least 8 states, 1 of the indications for medical marijuana is posttraumatic stress disorder (PTSD). 2 The current circumstances create an awkward situation in which researchers must evaluate the safety and efficacy of medical marijuana after its approval for various indications, including PTSD.

NEED FOR RESEARCH

Despite claims of medical use, marijuana remains illegal. Currently, in the United States marijuana remains listed as a Schedule I drug, meaning that there is a high abuse potential and no accepted medical use. Despite this, there are a growing number of claims that marijuana, particularly in the smoked form, has medical benefits. Indeed, early National Institutes of Health (NIH)–sponsored studies supported the claim that marijuana decreased nausea and vomiting in chemotherapy patients, resulting in FDA approval of a synthetic form of oral cannabis. Later, FDA approval for synthetic cannabis was extended to AIDS wasting syndrome. 3 This approval resulted in a multitude of claims of the benefits of marijuana for other potential conditions, leading to 2 large government-sponsored studies into the use of medical marijuana. 4 , 5 While both of these studies set out to finalize views on the matter, both ultimately found that there were simply too few scientific studies to determine the utility of medical marijuana; however, both concluded further research on the matter was justified. 3 This article seeks to review the existent literature to help determine the current state of such studies in regard to the use of medicinal marijuana in the treatment of PTSD.

METHOD

Potential studies for inclusion were identified by querying PubMed and PsycINFO for various combinations of the terms marijuana, medicinal marijuana, cannabis, cannabinoid, PTSD, efficacy, trial, and neurobiology up to April 2014. Duplicate studies were removed from inclusion. Articles adopting descriptive, observational, analytic, and experimental studies of both human and animal trials were considered for establishing proposed neurobiological basis. As such, animal studies, case studies, qualitative articles, reviews, and commentaries were reviewed. Given the limited number of studies on this topic, all were considered for inclusion. Full text of each article was reviewed, and those directly addressing the question of efficacy of medicinal marijuana on PTSD symptomatology were included. Data were extracted from a total of 46 articles.

RESULTS

Who Uses Medicinal Marijuana?

Despite the lack of established medical use, marijuana is currently used for a number of conditions. Most commonly, medical marijuana users were found to be male, white, between 25 and 44 years of age, and employed. 6 Reportedly, the most commonly cited primary uses for medical marijuana were pain, ranging between 82.6% and 92.2% of subjects, followed by muscle spasm (21%–41.3%). 6 , 7 Other reported primary uses included headaches, anxiety, insomnia, relaxation, poor appetite, nausea, and vomiting. 6 Interestingly, in states that allow for use of medical marijuana for traumatic intrusions and PTSD, this was listed as the primary indication in 38.5% of registered users. 7

Studies Evaluating Use in PTSD

To date, there has been little research investigating the relationship between marijuana use and PTSD. Existing studies have mostly focused on the tendency of individuals who suffer PTSD symptoms to self-medicate with marijuana. Undoubtedly, marijuana has long been reported as a coping mechanism for individuals with heightened PTSD symptoms. 8 – 10 It has been suggested that individuals with less perceived ability to withstand emotional distress were more likely to attempt to self-soothe with marijuana in response to distressing emotions related to trauma. Additionally, those with more symptomatology associated with PTSD were suggested to be more likely to use marijuana with the explicit purpose of coping. 11 Bonn-Miller et al 8 suggested that patients with more severe PTSD symptoms may be more motivated to use cannabis. In their study, marijuana use positively correlated with PTSD symptoms and, according to self-reports, cannabis was used with intent to cope with these PTSD symptoms. 8 Indeed, the mere fact that an individual carries a diagnosis of PTSD significantly increases his or her chance of using marijuana at some point in life, 12 a relationship that also holds true even among teenagers. 13 , 14

See also  Best cbd oil for seizure disorder

Cannabis use has been associated with a decrease in symptomatology, but may also be associated with higher risk of cannabis use disorder. Greer et al 15 reported a 75% reduction in Clinician Administered Posttraumatic Scale for DSM-IV (CAPS) scores through use of medical marijuana, and cannabis has been reported to be particularly helpful among persons with severe traumatic intrusions, 16 commonly referred to as flashbacks, as well as for managing hyperarousal symptoms. 17 Many people suffering from PTSD often have interrupted sleep, with many seeking medical marijuana as a means of helping them treat their sleep issues; however, while marijuana may help with sleep in the short term, it may also interfere with long-term sleep structure. 18 , 19 Cannabis has also been shown to have anxiolytic and anxiogenic properties depending on the primary cannabinoid. 20 The perceived sense of anxiolytic relief from cannabis may drive the high prevalence rates and co-occurrence between PTSD and cannabis use, 17 , 21 , 22 though arguments do exist that anxiety (including PTSD) and depression are associated with problematic cannabis use patterns and dependence. 12 , 23 – 27 Several studies have shown an increased chance of cannabis use disorders among adults suffering from, in particular, PTSD. 12 , 23 , 28 , 29 Boden et al 30 explained this phenomenon by suggesting “(a) the experience of PTSD predisposes affected individuals to use cannabis to cope with negative internal states, (b) discontinuation of cannabis use (even temporarily) paradoxically leads to greater PTSD symptomatology, via withdrawal, resulting in (c) heightened craving for cannabis, and (d) greater cannabis use problems as well as relapse to cannabis use to cope with increased negative internal states.” (p282) Further, increasing rates of cannabis use disorder diagnoses have been documented among military veterans, 22 , 23 especially those who endorse high rates of trauma exposure and PTSD. 31 – 35 With the large number of young men and women returning from war with traumatic experiences, veterans appear to be at particular risk for potential cannabis use disorders as a result. Therefore, determining the true causal relationship has never been more important.

Proposed Neurobiological Mechanisms

Marijuana is not just a single drug; it is a mixture of leaves from the Cannabis sativa plant and contains more than 400 chemicals with over 60 of these referenced as cannabinoids. Perhaps the most well-known and well-studied, delta-9-tetrahydrocannabinol (THC), is the main psychoactive cannabinoid. While ingested in a number of forms, once in the body, THC interacts with the cannabinoid receptors. There are 2 main cannabinoid receptors. Cannabinoid receptor 2 (CB2) is thought to exist primarily external to the central nervous system (CNS). CB2 is thought to exert its main effects on the immune and reproductive systems 3 , 36 , 37 and is thought responsible for the reported alleviating effects of cannabis on autoimmune dysfunction and potentiation of inflammatory reactions. 37 Given the limited neurologic interaction of CB2, this article will focus on cannabinoid receptor 1 (CB1), which is believed to be responsible for most, if not all, of the psychoactive effects of THC. 3 , 37

Purportedly the most abundant receptor in the brain, the actual density of CB1 receptors varies. Brain regions with the highest concentrations of CB1 receptors are in areas primarily involved in memory formation (hippocampus), motor coordination (the cerebellum), and emotionality (prefrontal cortex). 37 This distribution correlates well with reported effects of THC on human behavior: modulation of pain, regulation of appetite, regulation of pleasure, memory formation, concentration, sensory and time perception, and coordination of movement and motor function, as well as abuse and addictive potential. 3 , 37 , 38 An example of such an effect on human behaviors is the reported correlation between cannabis and decreased hyperarousal states. The modulation of the “fight or flight” response occurs largely in the amygdala; animal studies have demonstrated that electrical stimulation of various regions of the amygdala can send the animal into states of terror or surreal calm. There is a heavy concentration of CB1 receptors and endocannabinoids in the amygdala, which may help explain why low-dose cannabinoid stimulation is generally felt as calming. 39 Indeed, transgenic mouse models have shown that CB1 overexpression decreases excessive excitatory neurotransmission in these brain areas, which may explain the decreased arousal symptoms, as well as reduction of anxiety associated with cannabis use. 40 Given that hypervigilance and hyperarousal are symptoms of PTSD, this correlation may help explain, at least in part, the proposed benefit of cannabis for patients with PTSD. 17 , 23

One commonly reported side effect of chronic cannabis abuse is impairment in short-term memory. At first this may sound unwanted, but at times, it may be desirable to forget negative traumatic events and so may be potentially useful in treatment of PTSD. 3 Animal experiments have demonstrated that it took cannabinoid-deficient CB1 knock-out mice significantly longer to forget an association with painful foot shocks and bell ringing than wild-type controls, but both groups continued to make positive associations, suggesting THC may facilitate the extinction of negative memory without affecting positive memory formation. 41 – 43 Reciprocally, when the endocannabinoid system was activated through slowing of breakdown of endogenous cannabinoids, animal models demonstrated the ability to dissociate negative associations faster than in their normal state, leading to proposed involvement of the endocannabinoid system in the extinction of aversive memory. 43 Indeed, it may be this trait of cannabis that drives persons with PTSD to seek out and, at times, abuse cannabis. 16 However, this correlation has not yet been investigated in a well-structured clinical setting. 16 , 37 , 43

External stimulation of CB1 may not fully explain extinction of aversive memories. While CB1 knockout mice may require more time to forget adverse memories, so do mice with blockade of the endocannabinoid system. 41 , 42 Indeed administering THC on a chronic basis reduces the number of available cannabinoid receptors by 20%–60%, which effectively leaves the body’s natural endocannabinoids with fewer sites to activate, which may reduce their overall impact. 44 Some have attempted to reconcile this incongruity by suggesting the extinction response is due to fatty acid amide hydrolase, the enzyme that degrades endocannabinoids. 45 Clearly, more studies are needed on this matter. Another argument against mere stimulation of CB1 focused on the exclusive use of classical conditioning in the extinction studies, as this is seen as far removed from the experiences that result in PTSD in which the stressor is often seen as being of “human design.” 44 Indeed, as critics of medical marijuana have observed, no amount of numbing of PTSD is likely to help veterans process the deep grief and pain of having participated in the human tragedy of war. 44 , 46

CONCLUSION

In summary, cannabis is the most widely used illicit substance in the United States. With a growing number of states seeking to legalize marijuana for medicinal purposes, there is a need for a better understanding regarding the mechanism of action and efficacy of cannabis for the conditions for which it is prescribed. This article sought to review the existing literature regarding the use of cannabis for PTSD. To date, there is no large-scale, randomized, controlled study investigating efficacy of marijuana and PTSD symptomatology; however, the literature that exists suggests that it may have an effect on decreasing PTSD symptoms, and the neurobiological and animal studies seem to suggest potential underlying mechanisms consistent with these findings. However, PTSD may also be related to problematic, pathological use of cannabis. Additionally, the overall literature may be limited by publication bias, and the lack of standardized, large-scale controlled trials at this time makes any final conclusions on the efficacy uncertain. As the number of people seeking medical marijuana as well as those self-medicating for PTSD continues to rise, there is a clear need for more research trials and monitoring of the long-term effects of using cannabis for the treatment of PTSD and other medical conditions. Until then, given the limited evidence, physicians need to use their own clinical judgment when weighing the potential risks and benefits for a particular patient.

Potential conflicts of interest:

The author has no connection with tobacco, alcohol, pharmaceutical, or gaming industries or any entity funded by one of these organizations.

Funding/support:

References

1. Substance Abuse Mental Health Services Administration (SAMHSA) Rockville, MD: US Department of Health and Human Services; Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings. http://www.samhsa.gov/data/sites/default/files/Revised2k11NSDUHSummNatFindings/Revised2k11NSDUHSummNatFindings/NSDUHresults2011.htm. Updated September 2012. Accessed March 23, 2015. [Google Scholar]

2. Medical Marijuana Pros and Cons. 23 legal medical marijuana states and DC: laws, fees, and possession limits; 2014. ProCon.org. Web site. http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881. Updated January 8, 2015. Accessed August 25, 2014. [Google Scholar]

3. Volkow N. Marijuana and medicine: the need for a science-based approach. In: Stanford M, Avoy D, editors. Professional Perspectives on Addiction Medicine, Volume 2: Beyond Medical Marijuana: Toward Cannabinoid-Based Medicines. San Jose, CA: Santa Clara Valley Health & Hospital System, Department of Alcohol & Drug Services, Addiction Medicine and Therapy Program; 2009. pp. 24–28. [Google Scholar]

4. National Institutes of Health. Paper presented at the National Institute of Health Conference; February 19–20, 1997; Bethesda, MD: Ad Hoc Group of Experts. Workshop on the medical utility of marijuana: report to the director. [Google Scholar]

5. Watson SJ, Benson JA, Jr, Joy JE. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry. 2000; 57 (6):547–552. [PubMed] [Google Scholar]

6. Nunberg H, Kilmer B, Pacula RL, et al. An analysis of applicants presenting to a medical marijuana specialty practice in California. J Drug Policy Anal. 2011;(1):4. pii:1. [PMC free article] [PubMed] [Google Scholar]

7. Bowles DW. Persons registered for medical marijuana in the United States. J Palliat Med. 2012; 15 (1):9–11. [PubMed] [Google Scholar]

8. Bonn-Miller MO, Vujanovic AA, Feldner MT, et al. Posttraumatic stress symptom severity predicts marijuana use coping motives among traumatic event–exposed marijuana users. J Trauma Stress. 2007; 20 (4):577–586. [PubMed] [Google Scholar]

9. Zvolensky MJ, Vujanovic AA, Bernstein A, et al. Marijuana use motives: a confirmatory test and evaluation among young adult marijuana users. Addict Behav. 2007; 32 (12):3122–3130. [PMC free article] [PubMed] [Google Scholar]

10. Johnson K, Mullin JL, Marshall EC, et al. Exploring the mediational role of coping motives for marijuana use in terms of the relation between anxiety sensitivity and marijuana dependence. Am J Addict. 2010; 19 (3):277–282. [PMC free article] [PubMed] [Google Scholar]

11. Potter CM, Vujanovic AA, Marshall-Berenz EC, et al. Posttraumatic stress and marijuana use coping motives: the mediating role of distress tolerance. J Anxiety Disord. 2011; 25 (3):437–443. [PMC free article] [PubMed] [Google Scholar]

12. Cougle JR, Bonn-Miller MO, Vujanovic AA, et al. Posttraumatic stress disorder and cannabis use in a nationally representative sample. Psychol Addict Behav. 2011; 25 (3):554–558. [PubMed] [Google Scholar]

13. Cornelius JR, Kirisci L, Reynolds M, et al. PTSD contributes to teen and young adult cannabis use disorders. Addict Behav. 2010; 35 (2):91–94. [PMC free article] [PubMed] [Google Scholar]

14. Bujarski SJ, Feldner MT, Lewis SF, et al. Marijuana use among traumatic event–exposed adolescents: posttraumatic stress symptom frequency predicts coping motivations for use. Addict Behav. 2012; 37 (1):53–59. [PubMed] [Google Scholar]

15. Greer GR, Grob CS, Halberstadt AL. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. J Psychoactive Drugs. 2014; 46 (1):73–77. [PubMed] [Google Scholar]

16. Bonn-Miller MO, Boden MT, Bucossi MM, et al. Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. Am J Drug Alcohol Abuse. 2014; 40 (1):23–30. [PubMed] [Google Scholar]

17. Bremner JD, Southwick SM, Darnell A, et al. Chronic PTSD in Vietnam combat veterans: course of illness and substance abuse. Am J Psychiatry. 1996; 153 (3):369–375. [PubMed] [Google Scholar]

18. Babson KA, Bonn-Miller M. Sleep disturbances: implications for cannabis use, cannabis use cessation, and cannabis use treatment. Current Addiction Reports. 2014; 1 (2):109–114. [Google Scholar]

19. Bonn-Miller MO, Babson KA, Vandrey R. Using cannabis to help you sleep: heightened frequency of medical cannabis use among those with PTSD. Drug Alcohol Depend. 2014; 136 :162–165. [PMC free article] [PubMed] [Google Scholar]

20. Crippa JA, Zuardi AW, Martín-Santos R, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol. 2009; 24 (7):515–523. [PubMed] [Google Scholar]

21. Calhoun PS, Sampson WS, Bosworth HB, et al. Drug use and validity of substance use self-reports in veterans seeking help for posttraumatic stress disorder. J Consult Clin Psychol. 2000; 68 (5):923–927. [PubMed] [Google Scholar]

22. Bonn-Miller MO, Harris AH, Trafton JA. Prevalence of cannabis use disorder diagnoses among veterans in 2002, 2008, and 2009. Psychol Serv. 2012; 9 (4):404–416. [PubMed] [Google Scholar]

23. Bonn-Miller MO, Vujanovic AA, Drescher KD. Cannabis use among military veterans after residential treatment for posttraumatic stress disorder. Psychol Addict Behav. 2011; 25 (3):485–491. [PubMed] [Google Scholar]

24. Buckner JD, Heimberg RG, Schneier FR, et al. The relationship between cannabis use disorders and social anxiety disorder in the National Epidemiological Study of Alcohol and Related Conditions (NESARC) Drug Alcohol Depend. 2012; 124 (1–2):128–134. [PMC free article] [PubMed] [Google Scholar]

25. Degenhardt L, Hall W, Lynskey M. Exploring the association between cannabis use and depression. Addiction. 2003; 98 (11):1493–1504. [PubMed] [Google Scholar]

26. Zvolensky MJ, Bernstein A, Sachs-Ericsson N, et al. Lifetime associations between cannabis, use, abuse, and dependence and panic attacks in a representative sample. J Psychiatr Res. 2006; 40 (6):477–486. [PubMed] [Google Scholar]

27. Zvolensky MJ, Lewinsohn P, Bernstein A, et al. Prospective associations between cannabis use, abuse, and dependence and panic attacks and disorder. J Psychiatr Res. 2008; 42 (12):1017–1023. [PMC free article] [PubMed] [Google Scholar]

28. Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995; 52 (12):1048–1060. [PubMed] [Google Scholar]

29. Stewart SH, Pihl RO, Conrod PJ, et al. Functional associations among trauma, PTSD, and substance-related disorders. Addict Behav. 1998; 23 (6):797–812. [PubMed] [Google Scholar]

30. Boden MT, Babson KA, Vujanovic AA, et al. Posttraumatic stress disorder and cannabis use characteristics among military veterans with cannabis dependence. Am J Addict. 2013; 22 (3):277–284. [PubMed] [Google Scholar]

31. Hoge CW, Castro CA, Messer SC, et al. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med. 2004; 351 (1):13–22. [PubMed] [Google Scholar]

32. Institute of Medicine Committee on the Initial Assessment of Readjustment Needs of Military Personnel V. Washington, DC: National Academies Press; 2010. Returning Home from Iraq and Afghanistan: Preliminary Assessment of Readjustment Needs of Veterans, Service Members, and Their Families. [PubMed] [Google Scholar]

33. McFall ME, Mackay PW, Donovan DM. Combat-related posttraumatic stress disorder and severity of substance abuse in Vietnam veterans. J Stud Alcohol. 1992; 53 (4):357–363. [PubMed] [Google Scholar]

34. Reifman A, Windle M. Vietnam combat exposure and recent drug use: a national study. J Trauma Stress. 1996; 9 (3):557–568. [PubMed] [Google Scholar]

35. Rosen C, Greenbaum M, Fitt J. Poster presented at the Annual VA Health Services Research & Development Conference. February 13, 2008; Baltimore, MD: Demand for and utilization of VA outpatient mental health care for PTSD: 2001–2007. [Google Scholar]

36. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993; 365 (6441):61–65. [PubMed] [Google Scholar]

37. Maximillian P. The endocannabinoid system. In: Stanford M, Avoy D, editors. Professional Perspectives on Addiction Medicine, Volume 2: Beyond Medical Marijuana: Toward Cannabinoid-Based Medicines. San Jose, CA: Santa Clara Valley Health & Hospital System Department of Alcohol & Drug Services Addiction Medicine and Therapy Program; 2009. pp. 32–41. [Google Scholar]

38. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346 (6284):561–564. [PubMed] [Google Scholar]

39. Schwartz CE, Wright CI, Shin LM, et al. Differential amygdalar response to novel versus newly familiar neutral faces: a functional MRI probe developed for studying inhibited temperament. Biol Psychiatry. 2003; 53 (10):854–862. [PubMed] [Google Scholar]

40. Guggenhuber S, Monory K, Lutz B, et al. AAV vector-mediated overexpression of CB1 cannabinoid receptor in pyramidal neurons of the hippocampus protects against seizure-induced excitoxicity. PLoS ONE. 2010; 5 (12):e15707. [PMC free article] [PubMed] [Google Scholar]

41. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002; 418 (6897):530–534. [PubMed] [Google Scholar]

42. Chhatwal JP, Davis M, Maguschak KA, et al. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology. 2005; 30 (3):516–524. [PubMed] [Google Scholar]

43. Lutz B. The endocannabinoid system and extinction learning. Mol Neurobiol. 2007; 36 (1):92–101. [PubMed] [Google Scholar]

44. Cermack T. Medical marijuana. In: Stanford M, Avoy D, editors. Professional Perspectives on Addiction Medicine, Volume 2: Beyond Medical Marijuana: Toward Cannabinoid-Based Medicines. San Jose, CA: Santa Clara Valley Health & Hospital System Department of Alcohol & Drug Services Addiction Medicine and Therapy Program; 2009. p. 71. [Google Scholar]

45. Varvel SA, Wise LE, Niyuhire F, et al. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology. 2007; 32 (5):1032–1041. [PubMed] [Google Scholar]

Articles from The Primary Care Companion for CNS Disorders are provided here courtesy of Physicians Postgraduate Press, Inc.